SMARCD2 and acute myeloid leukemia: Intersecting the restored sites achieved by WT SMARCD2 and R290W SMARCD2 identified a collection of 19,656 sites that required WT SMARCD2 for mSWI/SNF targeting in AML cells (Fig. 4D, S7F).